Although the study was not powered to make a direct comparison, these data may suggest a more frequent increase in CD8+ cell infiltration in patients with BRAF-mutated melanoma receiving BRAF plus MEK inhibitors with anti-PD-L1 therapy than in patients with BRAF-wild type melanoma receiving the MEK inhibitor with anti-PD-L1 therapy. This evidence concerns the gene CD8A and melanoma.